Targeted EGFRvIII autochimeric antigen receptor T cell therapy (DCTY)

N/A

Report date: 2025/09/30 10:44:58

Base Information

Drug NameTargeted EGFRvIII autochimeric antigen receptor T cell therapy (DCTY)
Drug Alias NameTargeted Epidermal Growth Factor Receptor Variant III(EGFRvIII) autochimeric antigen receptor T cell therapy (DCTY)EGFRvIII CAR-T cell therapy (DCTY)DCTY0801 Autologous T lymphocyte cell therapy (DCTY)DCTY0801DCTY-0801
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionAnti-EGFRvIII
TargetsEpidermal growth factor receptor variant III
Therapy Area/IndicationsGlioblastomaGlioma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesBeijing DCTY Biotech Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBeijing DCTY Biotech Co Ltd
Inactive CompaniesN/A
Active IndicationsGlioblastomaGlioma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A